Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Tseng, Jeng Sen ^a,b   Wang, Chih Liang ^c,d   Huang, Ming Shyan ^e,f   Chen, Chung Yu ^g   Chang, Cheng Yu ^h   Yang, Tsung Ying ^a,i   Tsai, Chi Ren ^a,b   Chen, Kun Chieh ^a,b   Hsu, Kuo Hsuan ^a,b   Tsai, Meen Hsin ^a,j   Yu, Sung Liang ^g,k   Su, Kang Yi ^k,l   Wu, Chih Wei ^m   Yang, Cheng Ta ^c,n   Chen, Yuh Min ^m,o   Chang, Gee Chen ^a,i  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

ⁱ NATIONAL YANG MING UNIVERSITY   (Taiwan)

^j INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^k NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^l NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^m TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

ⁿ CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^o TAIPEI MEDICAL UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; QUINAZOLINE DERIVATIVE;

ADULT; AGED; AMPLIFICATION REFRACTORY MUTATION SYSTEM; ARTICLE; CONTROLLED STUDY; DIRECT SEQUENCING; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; EGFR GENE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; INTERMETHOD COMPARISON; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEASUREMENT ACCURACY; MIDDLE AGED; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; SEQUENCE ANALYSIS; TAIWAN; VERY ELDERLY; WILD TYPE; ADENOCARCINOMA; CANCER STAGING; COHORT ANALYSIS; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84926038463     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107160     Document Type: Article

References (39)

1. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, et al. (2013) Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 105: 595-605.
2. Chen G, Feng J, Zhou C, Wu YL, Liu XQ, et al. (2013) Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol 24: 1615-1622.
3. Thongprasert S, Duffield E, Saijo N, Wu YL, Yang JC, et al. (2011) Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 6: 1872-1880.
4. Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, et al. (2013) Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 31: 3342-3350.
5. Leighl NB (2012) Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol 19: S52-58.
6. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF (2013) Management of non-small-cell lung cancer: recent developments. Lancet 382: 709-719.
7. Chen YM, Tsai CM, Fan WC, Shih JF, Liu SH, et al. (2012) Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older. J Thorac Oncol 7: 412-418.
8. Kobayashi T, Koizumi T, Agatsuma T, Yasuo M, Tsushima K, et al. (2012) A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 69: 1241-1246.
9. Tseng JS, Yang TY, Chen KC, Hsu KH, Chen HY, et al. (2012) Retrospective study of erlotinib in patients with advanced squamous lung cancer. Lung Cancer 77: 128-133.
10. Azzoli CG, Temin S, Giaccone G (2012) 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract 8: 63-66.
11. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, et al. (2012) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 Suppl 7: vii56-64.
12. National Comprehensive Cancer Network (2014) The NCCN clinical practice guidelines in oncology (NCCN guidelines) for non-small cell lung cancer. Version 3.2014. http://www.nccn.org.
13. Jazieh AR, Al Sudairy R, Abu-Shraie N, Al Suwairi W, Ferwana M, et al. (2013) Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review. Ann Thorac Med 8: 204-208.
14. Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, et al. (2007) Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 131: 1628-1634.
15. Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, et al. (2010) A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol 5: 99-104.
16. Naoki K, Soejima K, Okamoto H, Hamamoto J, Hida N, et al. (2011) The PCR-invader method (structure-specific 59 nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. Int J Clin Oncol 16: 335-344.
17. Yang TY, Tsai CR, Chen KC, Hsu KH, Lee HM, et al. (2011) Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene. J Clin Oncol 29: e468-469.
18. Chiu CH, Ho HL, Chiang CL, Lin SF, Ma HH, et al. (2014) Clinical characteristics and treatment outcomes of lung adenocarcinomas with discrepant EGFR mutation testing results derived from PCR-direct sequencing and realtime PCR-based assays. J Thorac Oncol 9: 91-96.
19. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, et al. (2011) Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 29: 3316-3321.
20. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, eds. AJCC Cancer Staging Handbook. 7th ed. New York: Springer; 2009.
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
22. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, et al. (2005) Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11: 3750-3757.
23. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, et al. (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17: 2503-2516.
24. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, et al. (2012) Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 30: 433-440.
25. EGFR RGQ PCR Kit Product Details. Available: http://www.qiagen.com/products/catalog/assay-technologies/complete-assay-kits/personalized-healthcare/egfr-rgq-pcr-kit-productdetails/. Accessed 2014 July 29.
26. Kimura H, Ohira T, Uchida O, Matsubayashi J, Shimizu S, et al. (2014) Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. Lung Cancer 83: 329-333.
27. Yeh P, Chen H, Andrews J, Naser R, Pao W, et al. (2013) DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin Cancer Res 19: 1894-1901.
28. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8: 823-859.
29. Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, et al. (2012) Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer 75: 321-325.
30. Er TK, Lin CW, Liu TC, Chen CC, Wang LH, et al. (2014) Increase EGFR Mutations Detection Rate in Lung Adenocarcinoma by Real-Time PCR Screening Followed by Direct Sequencing. Diagn Mol Pathol.
31. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, et al. (2011) Effectiveness of tyrosine kinase inhibitors on ''uncommon'' epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 17: 3812-3821.
32. Catalogue of Somatic Mutations in Cancer. [http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/.
33. Chiang CL, Tsai CM, Chou TY, Chen YM, Lai SL, et al. (2013) Erlotinib in patients with advanced lung squamous cell carcinoma. Cancer Chemother Pharmacol 71: 203-208.
34. Wang F, Fu S, Shao Q, Zhou YB, Zhang X, et al. (2013) High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR. J Transl Med 11: 90.
35. Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, et al. (2011) Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res 71: 7587-7596.
36. Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, et al. (2014) CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. Lung Cancer 85: 152-160.
37. Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, et al. (2014) Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol 15: 713-721.
38. Wu K, Huang RS, House L, Cho WC (2013) Next-generation sequencing for lung cancer. Future Oncol 9: 1323-1336.
39. Couraud S, Vaca Paniagua F, Villar S, Oliver J, Schuster T, et al. (2014) Non-invasive diagnosis of actionable mutations by deep sequencing of circulating-free DNA in non-small cell lung cancer: Findings from BioCAST/IFCT-1002. Clin Cancer Res.